![Page 1: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/1.jpg)
![Page 2: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/2.jpg)
A study into the urgent endoscopy referral system for
patients with suspected gastrointestinal cancer
Christopher Jump
3rd Year Medical Student
![Page 3: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/3.jpg)
Background information
• With the aim of improving the detection of cancers at an early stage and therefore survival rates the 2-week referral system was introduced in 2000 by the Department of Health and was revised in 2005 by NICE
• This included a referral form which specified symptoms that needed to be present in order for the patient to be urgently referred to a specialist consultation or directly to endoscopy
![Page 4: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/4.jpg)
Reasons the study was needed
• Many patient’s specimens referred as urgent to the
histopathologist are not diagnosed with malignancy.
This displaces ‘correctly’ referred urgent patients
down the waiting list, potentially causing them a
worse prognosis due to the delay of diagnosis and
subsequent treatment
![Page 5: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/5.jpg)
Reasons the study was needed
• Each colonoscopy costs about £900
• Each oesophagogastroduodenoscopy (OGD) costs about £500-
600
• Histopathology costs are about:
o £67 per single biopsy site
o £100 for 2 biopsy sites
o £133 for 3 biopsy sites
• The PCT pays for each one they refer for, so if they are not
necessary it is a waste of their limited budget
![Page 6: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/6.jpg)
Reasons the study was needed
• There are significant complications associated with
all types of endoscopy, which patients are being
needlessly exposed to if they are incorrectly referred
• E.g. Perforation, haemorrhage, infection, pain and
discomfort, sedation associated (cardio-pulmonary
events), etc.
![Page 7: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/7.jpg)
Current evidence base
• Limited number of studies investigating urgent referral
for endoscopy in GI cancer patients, most of which
look into therapeutic endoscopy
• Many studies looking into the effectiveness of the
guidelines for urgent referral to a specialist in
secondary care. Have shown mixed results regarding
if the guidelines are specific enough to detect early
cancer presentation and their effect on the outcome of
patients
![Page 8: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/8.jpg)
Main aims of the study
• To investigate:
o The number of patients that are correctly and
incorrectly referred for urgent endoscopies
o The differences in outcome between the patients
who were correctly and incorrectly referred
![Page 9: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/9.jpg)
Method
• 50 patients included in the study, 25 who underwent an upper GI
endoscopy and 25 who had a lower GI endoscopy between the
25th February and 17th March 2009 at Southport and Formby
District General Hospital.
• Patients were identified by urgent histopathology referral forms.
• Medical records were then accessed and data collected.
• Urgent referrals were deemed to be correct or incorrect using
‘NICE referral for suspected cancer guidelines’.
• Outcomes were recorded by assessing their progress since their
endoscopy.
![Page 10: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/10.jpg)
Results
• Mean age of 72.1 years
• 25 males and 25 females in total sample
• When divided:
o 14 females and 11 males in upper GI group
o 11 females and 14 males in lower GI group
![Page 11: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/11.jpg)
Results- Source of referrals
• 43 (86%) of the 50 patients were referred from a GP
• 4 from hospital wards
• 1 from A&E, 1 referred by MDT, 1 surveillance
![Page 12: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/12.jpg)
Results- Number of correct and incorrect referrals
• 18 (36%) of 50 patients were referred in accordance with NICE
guidelines
• When divided:
o Upper GI= 4 correct and 21 incorrect referrals
o Lower GI= 14 correct and 11 incorrect referrals
![Page 13: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/13.jpg)
Results- what the upper GI referrals should have been
• Of the 21 incorrect referrals:
o 12 should have been given an urgent outpatient referral
o 5 should have been considered for an urgent outpatient referral
o 4 should have been routinely referred for an outpatient appointment
![Page 14: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/14.jpg)
Results- Outcomes of correct referrals
• Upper GI:
o 1 patient with a benign polyp, now on surveillance
o 1 patient with an oesophageal ulcer and gastritis (PPI and discharged)
o 1 patient with duodenitis, duodenal ulcer, gastritis and 2 gastric ulcers
(PPI and discharged)
o 1 patient with gastritis and duodenitis (PPI and discharged)
• Lower GI:
o 5 cancers; 3 died, 1 is treated palliatively and 1 had surgical excision
and is now under surveillance
o 2 patients with Diverticular Disease discharged
o 2 patients with benign polyps discharged
o 5 patients normal, discharged
![Page 15: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/15.jpg)
Results-Outcome of correct referrals
![Page 16: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/16.jpg)
Results-Outcome of incorrect referrals
• Upper GIo 3 patients died (2 cancers, 1 unknown)o 13 patients treated for an inflammatory condition (oesophagitis,
gastritis or duodenitis) with a PPI and discharged.o 2 patients normalo 2 treated for malignancy (partial gastrectomy, oesophageal stent)o 1 patient continued on surveillance for Barrett’s oesophagus
![Page 17: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/17.jpg)
Results-Outcome of incorrect referrals
• Lower GI:o 3 malignancies detected; 2 had successful surgical excisions,
1 treated palliativelyo 3 patients had adenomatous polyps excised, now under
surveillanceo 2 normal patientso 1 with haemorrhoids, dischargedo 2 treated for ulcerative colitis (both medication, 1 also had a
colectomy)
![Page 18: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/18.jpg)
What has it shown
• Minority (36%) of urgent referrals comply with guidelines
• Majority (81%) of incorrect referrals are from GPs
• There are considerably more upper GI than lower GI incorrect
urgent referrals for endoscopy (21/25- 11/25)
• Minority of patients who are urgently referred for endoscopy
are diagnosed with cancer (24%)
• The incorrect referrals detected more cancers than the correct
referrals (7-5)
![Page 19: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/19.jpg)
What has it shown
• Correct upper GI referrals detected no cancers, incorrect
detected 4
• Correct lower GI referrals detected 5 cancers, incorrect detected
3
• Incorrect lower GI referrals had a higher curative treatment rate
for cancer than correct lower GI referrals (66.7%-20%)
• 3 patients out of 50 had life saving surgical resection of their
cancer over the 3 weeks this study observed
• Equates to 52 patients a year saved at an annual cost of about
£718,363 for endoscopy and histopathology only
![Page 20: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/20.jpg)
Conclusions• The existing guidelines are not effective as originally hoped in detecting patients
with gastrointestinal cancer
• This study suggests that for a cancer to meet the current urgent referral
guidelines it has to be at a late enough stage to exhibit enough symptoms to fulfil
the criteria, with the majority of the time this being too late to cure the patient
• Guidelines need to be reviewed and amended with the aim of detecting more
cancers at an early stage
• Guidelines need to be made compulsory for all GPs as this is where the main
problem lies
![Page 21: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/21.jpg)
Limitations
• Symptoms in urgent referral form not specified,
which meant many patients may have been eligible
for urgent referral but were deemed not, as form not
filled in extensively enough. E.g. ‘rectal bleeding’ but
duration not specified
• Handwriting on some referral forms illegible so
patient may have met criteria
![Page 22: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/22.jpg)
Limitations
• Some patients had missing histology reports in their
medical files so information had to be taken from
consultants letter to GP, which contains less specific
information
• Sample size in this study is not large enough to
draw significant conclusions, so a possible future
study could expand on these findings with more
patients from a wider region
![Page 23: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/23.jpg)
Thank you for listening
![Page 24: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/24.jpg)
![Page 25: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/25.jpg)
Audit of Lung Biopsies Received at Whiston Hospital Histopathology Department in
2009
Dr S Kelly
Dr L Forsyth
Dr S A Melmore
![Page 26: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/26.jpg)
Aim
• To review all lung biopsies received at Whiston
in 2009.• To assess adequacy.• Try to further differentiate the non-small cell
carcinomas (NSCC) into adenocarcinoma (adenoca) and squamous cell carcinoma (SCC)– on morphology, and– with the aid of immunohistochemistry.
![Page 27: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/27.jpg)
Background
• Biopsy interpretation limited by – Sampling error,– Sample size,– Tumour heterogeneity.
• BTS guidelines (2001)recommend 90% adequacy with 5+ biopsies in cases of suspected malignancy.
![Page 28: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/28.jpg)
• Small cell carcinoma (SMCC) → chemotherapy.• NSCC → surgery.
• New medical treatments for adenoca – without squamous differentiation (folate
antimetabolite chemotherapy drugs under assessment by NICE), and
– with EGFR-TK mutations (EGFR-TK inhibitors).
![Page 29: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/29.jpg)
• Immunohistochemistry (IHC) may aid further differentiation.
• Limitations include;– inadequate sample size,– crush artefact,– positive staining of normal lung constituents,– overlapping immunophenotypes, and– previous studies conducted on resection
specimens and cytology but not biopsies.
![Page 30: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/30.jpg)
Immunohistochemistry
• Squamous cell carcinoma; CK5, p63 and 34βE12.
• Adenocarcinoma; CK7, CK20 and TTF1.• P63
– Nuclear, SCC 78-100%, adenoca 1-33%, SMCC 77%.
• CK 5/6– SCC 100%.
• TTF1– Nuclear, adenoca 68-85%, SMCC 84%, 5-21%
SCC.– Poorly differentiated more likely to be negative.
![Page 31: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/31.jpg)
SCC
H & E
TTF -ve
P63 +ve
![Page 32: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/32.jpg)
Adenoca
H & E
TTF +ve
P63 -ve
![Page 33: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/33.jpg)
Method
• Telepath search for all lung biopsies in 2009.• All cases reviewed by 2 consultants and 1 SpR.• Number of biopsy fragments counted.• Morphological diagnosis given.• All carcinoma NOS, 6 adenoca and 6 SCC →
– TTF-1 and p63. • TTF1 and p63 - ve →
– CK5/6– Case notes and reports from RLBUHT
reviewed.
![Page 34: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/34.jpg)
Results• Pieces 1 2 3 4 5 6
• Negative (9) 2 4 2 0 1 0• Suspicious (1) 0 0 1 0 0 0• Malignant (49) 4 12 17 7 5 4
• Total (64) 6 16 20 7 6 4• % of total 9.4 25 31.3 11 9.4
6.3Number of adequate = 15.7 %
![Page 35: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/35.jpg)
• Total 64
• Inadequate 5 • Negative 9• Low grade dysplasia, 1• Adenocarcinoma 9• Squamous cell carcinoma, 17• Carcinoma (NOS) 11 • Small cell carcinoma 8 • Metastatic or other 4
![Page 36: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/36.jpg)
Not satisfactory
TTF1+
p63+
TTF1+
p63-
TTF1 –
p63 +
TTF1-
p63 -
TTF1 +
p63 +/-
Adenoc 0 1 (17%)
5 (83%)
0 0 0
sqcc 2 0 0 4 (100%)
0 0
Carcinoma NOS
2 0 4 (44%)
0 4 (44%)
1 (11%)
![Page 37: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/37.jpg)
• 83% of adenocarcinoma TTF1 + (75-85% in studies).
• 1 adenocarcinoma TTF1 + p63 + (1-33% literature).
• 100% of satisfactory biopsies of sqcc p63 +.• 4 cases of carcinoma NOS TTF1 +, p63 -
probably adenocarcinoma.• 1 case p63 +/- , showed a positive internal
control. (Patient with cerebral metastases so no resection performed).
![Page 38: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/38.jpg)
P63 +/-ve
TTF +ve
CK 5/6 -ve
H & E
![Page 39: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/39.jpg)
• 4 cases TTF1 - ve, p63 – ve, – all internal controls for p63 + ve, and – all CK5/6 – ve. – 1 was small cell marker - ve on biopsy,
• resection showed a squamous cell carcinoma.
– 3 showed possible squamous morphology, • no resection due to the patient’s co-morbidities,
metastases or locally advanced disease.
![Page 40: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/40.jpg)
Conclusion
• We diagnosed 5/64 cases as inadequate on H&E.
• Only 10/64 (15.7%) of the remaining cases contained 5+ fragments of tissue.( vs. 90%).
• We made a morphological diagnosis of malignancy on 49/64 cases, (9/49 had 5+ biopsies), and
• Differentiated type on H&E in 38/49 cases (6/38 had 5+ biopsies).
• 4/23 cases sent for IHC were inadequate. – diagnosed on H&E as 2 x SCC, 2 x carcinoma NOS
![Page 41: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/41.jpg)
• Our cases are comparable with the literature for these robust IHC stains.
• For morphologically classic adenocarcinoma TTF1 and p63 can be used in combination to confirm the absence/presence of squamous differentiation.
• For poorly differentiated NSCC cells the use of TTF1 and p63 may aid further differentiation.
• Immunohistochemistry should be interpreted together with morphology and clinical history.
• Sub classification should be avoided if uncertain.
![Page 42: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/42.jpg)
• Limitations include;
– small sample size, – difficult morphology, – variable immunohistochemical staining and
interpretation,– tumour heterogeneity,– previous studies done on resection
specimens.
![Page 43: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/43.jpg)
The future
• As the prospect of mutational analysis on more/all of these tumours draws closer, and
• The use of IHC is used increasingly to choose the tumours that will benefit from treatment,
• Clinicians will need to be aware of – The need for an adequate sample, and– The impact on turnaround times will mean
• waiting for a delayed report, or
• receiving preliminary and supplementory reports.
![Page 44: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/44.jpg)
Recommendations
• Use TTF1 and p63; – to confirm squamous differentiation in
morphologically diagnosed adenocarcinoma,– in poorly differentiated NSCC but be aware of the
limitations.
• Cut spare sections on all levels for IHC.
• Check results of subsequent resections.
• Comment on BTS adequacy in reports.
• Disseminate this information to all histopathologists and relevant clinicians.
![Page 45: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/45.jpg)
Take Home Message
• For clinicians– An adequate sample is required for accurate
diagnosis, and – extensive IHC and mutational testing is time
consuming. • For pathologists
– Immunohistochemistry should ALWAYS be interpreted together with morphology and clinical history.
![Page 46: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/46.jpg)
Thank you
Any questions?
![Page 47: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/47.jpg)
![Page 48: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/48.jpg)
Cancer Data for Outcomes
Desperately Seeking
Your Support
‘We can only be sure to improve
what we can actually measure’
– Lord Darzi
NHS North West
Supplier Data Report 2010/11
Data Supply
Data Quality
![Page 49: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/49.jpg)
Poor SurvivalKey Questions?
• Stage at Presentation– Does my population have a problem with late stage
presentation? (not amenable to healthcare)– Do I know where and with whom there are delays in
presentation/delays in diagnosis?– Am I able to make informed investment/disinvestment
decisions?
• Access to Diagnosis and Treatment– Does the population and sub-populations of my PCT
access the right services at the right time?
![Page 50: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/50.jpg)
PROVIDER Pathology Comment
AINTREE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST GREEN
ALDER HEY CHILDREN'S NHS FOUNDATION TRUST
GREEN
04/10/2010 First electronic send. Received a file from Jan 2009 to June 2010. Receiving monthly sends thereafter
COUNTESS OF CHESTER HOSPITAL NHS FOUNDATION TRUST GREEN
ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST GREEN
Receipt re-established
SOUTHPORT AND ORMSKIRK HOSPITAL NHS TRUST RED
Still sending paper
ST HELENS AND KNOWSLEY HOSPITALS NHS TRUST GREEN
WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY NHS TRUST RED
Still sending paper
WARRINGTON AND HALTON HOSPITALS NHS FOUNDATION TRUST GREEN
WIRRAL UNIVERSITY TEACHING HOSPITAL NHS FOUNDATION TRUST RED
NO DATA RECEIVED SINCE MARCH 2010
March 2011 – Electronic PathPipe delimited txt files
![Page 51: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/51.jpg)
Pathology Mark Up
Breast
Laterality
Grade
No of Nodes
Size
![Page 52: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/52.jpg)
Timeliness
• Timeliness of Data Supply
• Timeliness of Data Quality Feedback– Don’t want to study history
• Timeliness of commentary on services as they are currently configured and delivered
![Page 53: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/53.jpg)
Summary
• Outcomes Framework a key driver for regular, high quality, timely cancer data
• Informed service planning depends upon high quality data – across patient pathway
• Need to achieve full electronic data supply by March 2011
• Leverage vital for a step change in data capture and reporting
![Page 54: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/54.jpg)
![Page 55: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/55.jpg)
Emerging technologies and targeting treatments: EGFR
JR GosneyConsultant Thoracic Pathologist
Royal Liverpool University Hospital
![Page 56: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/56.jpg)
Epidermal growth factor receptor (EGFR)
• EGFR (HER-1; ErbB1)
• HER-2 (neu; ErbB2)
• HER-3 (ErbB3)
• HER-4 (ErbB4)
![Page 57: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/57.jpg)
EGFR gene mutations and gefitinib
![Page 58: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/58.jpg)
Sensitising mutations of EGFR gene
• Classically in peripheral, well differentiated, acinar, non-mucinous adenocarcinomas with a bronchioloalveolar component
• About 60% of non-smoking, Eastern Asian women with adenocarcinoma
• About 10% of Western subjects with NSCLC
![Page 59: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/59.jpg)
EGFR protein expression
• Immunochemical detection of EGFR protein is not currently a reliable indicator of sensitising mutations nor of sensitivity to TKIs
![Page 60: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/60.jpg)
EGFR gene amplification
• High EGFR gene copy number is an imprecise reflection of mutational status and sensitivity to TKIs and its detection by in situ hybridization is time consuming and technically demanding
![Page 61: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/61.jpg)
Detecting mutations
• Mutations are detectable by screening or targeted detection– Trials of gefitinib employed an
amplification-refractory mutation system (ARMS)-based kit that targets 29 mutations in the EGFR gene
– This technique is sensitive and robust and does not require a high level of technical expertise
![Page 62: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/62.jpg)
EGFR mutational analysis
![Page 63: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/63.jpg)
In the Merseyside & North Cheshire Network
• About 750 new cases of NSCLC diagnosed by histo- or cytopathology per annum
• Paraffin wax block with accompanying report and H&E-stained section sent by referring pathologist to Department of Pathology at RLUH
• Histological assessment with possible microdissection followed by DNA extraction and mutational analysis
• Return of report of analysis to managing oncologist and to referring histopathology laboratory for integration with histopathology report
• Correlation of histopathology with mutational status for quality control, audit and development of service
![Page 64: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/64.jpg)
December 2009-November 2010
• Phillipe Tanière, University of Birmingham
• Funded by AstraZeneca
• Non-small cell lung cancer
• Any stage
• 200 cases sent for analysis
![Page 65: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/65.jpg)
December 2009-November 2010
• 96 male• 190 adenocarcinoma, 9 squamous, 1 LCNEC• 170 tissue biopsies, 15 cytology (10 FNAs (8
EBUS), 4 pleural fluid, 1 washing), 15 from resections
• 11 sensitizing mutations (5%)• 2 mutations conferring resistance (1%)• Mean turnaround time 15 days (8-34)
![Page 66: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/66.jpg)
Eleven sensitizing mutations
• Six male, five female• Two of Chinese, one of Pakistani origin• Eight new diagnoses: three needle cores, two
bronchial biopsies, one lymph node, one bronchial washings, one from wedge resection
• Three recurrent disease: one original needle biopsy, one vertebral metastasis, one from previous resection
• Six point mutations (one 719 exon 18; one 861 exon 21, four 858 exon 21), five deletions (all exon 19)
• Nine adenocarcinoma, two non-small cell carcinoma not otherwise specified
![Page 67: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/67.jpg)
From December 2010
• Mutational analysis at Royal Liverpool University Hospital
• Budget for analysis (and gefitinib) held at Clatterbridge Centre for Oncology
• Locally advanced or metastatic disease (according to license and NICE guidance)
• Non-squamous tumours only
![Page 68: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/68.jpg)
![Page 69: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/69.jpg)
Pooja Jain
Consultant Clinical Oncologist
Clatterbridge Centre for Oncology
![Page 70: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/70.jpg)
• EGFR in NSCLC
• Targeting EGFR– Tyrosine Kinase Inhibitors
• John Gosney
![Page 71: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/71.jpg)
• Key drivers in the process of – Cell growth– Proliferation
• EGFR activating mutation– promotion of tumour cell
growth– blocking of apoptosis– increasing the production of
angiogenic factors– facilitating the processes of
metastasis
• Dysregulation frequently seen in NSCLC
Tyrosine kinase Tyrosine kinase inhibitioninhibition
![Page 72: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/72.jpg)
• Initially developed as second line therapy– BR 21– Increase in the objective response rate (9% <1 %)– Increase in overall survival (6.7 versus 4.7 months)– Improvement in symptoms & physical function
• Early indication of selection– Women– Never/light smoker– Adenocarcinoma
![Page 73: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/73.jpg)
• First line therapy– Platinum doublet
• RR 30%• 65% of patients would be suitable
• Second line chemotherapy– 30% of patients would be suitable
• Single agent docetaxel/gemcitabine/vinorelbine• RR < 10%
![Page 74: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/74.jpg)
• Phase II studies: objective response rates of 55 to 90%
• IPASS study
• Phase III studies were in Far East– IPASS – WJTOG3405
![Page 75: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/75.jpg)
IRESSA
(250 mg daily)
Carboplatin (AUC 5 or 6) /
paclitaxel (200 mg / m2)
3 weekly#
1:1 randomisation
* Never smokers, <100 cigarettes in lifetime; light ex-smokers, stopped 15 years ago and smoked 10 pack years; # limited to a maximum of 6 cycles Carboplatin / paclitaxel was offered to IRESSA patients at progressionPS, performance status; EGFR, epidermal growth factor receptor
Patients•Chemonaïve
•Age ≥18 years
•Adenocarcinoma histology
•Never or lightex-smokers*
•Life expectancy≥12 weeks
•PS 0-2
•Measurable stage IIIB / IV disease
Primary• Progression-free survival (non-inferiority)
Secondary• Objective response rate• Overall survival • Quality of life• Disease-related symptoms • Safety and tolerability
Exploratory• Biomarkers
• EGFR mutation• EGFR-gene-copy number• EGFR protein expression
Endpoints
Mok et al 2009, Fukuoka 2009
![Page 76: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/76.jpg)
• IPASS exceeded it’s primary endpoint and demonstrated superiority for IRESSA in PFS compared to doublet chemotherapy
• PFS effect was not consistent over time
609453 (74.4%)
608497 (81.7%)
NEvents
HR (95% CI) = 0.741 (0.651, 0.845) p<0.0001
IRESSACarboplatin /
paclitaxel
Carboplatin / paclitaxel
IRESSA
Median PFS (months)4 months progression-free6 months progression-free12 months progression-free
5.761%48%25%
5.874%48%7%
609
212 76
24
5 0608
118
22
3 1 0363412
0 4 8 12
16
20 24 Months0.0
0.2
0.4
0.6
0.8
1.0
Pro
bab
ilit
y o
f P
FS
At risk :
IPA
SS
: P
rog
res
sio
n F
ree
Su
rviv
al (
ITT
)
Mok T, Wu TL, Thongprasert S et al. N Engl J Med 2009; 361:947-995
![Page 77: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/77.jpg)
43
32
05
101520253035404550
IR E S S A C arboplatin/P ac litaxel
Ov
era
ll R
es
po
ns
e R
ate
%(I
TT
Po
pu
lati
on
)
Overall Response Rate, ITT population
IPA
SS
: O
ver
all
Res
po
ns
e R
ate
(IT
T)
IRESSA produced a greater ORR than doublet chemotherapy in a clinically selected group of patients
Odds ratio = 1.59 (95% CI 1.25, 2.01) p=0.0001
Mok T, Wu TL, Thongprasert S et al. N Engl J Med 2009; 361:947-995
![Page 78: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/78.jpg)
• IRESSA halved the relative risk of progression compared with carboplatin/ paclitaxel in EGFR M+ patients1
• Median PFS was over 3 months longer with IRESSA in EGFR M+ patients than carboplatin/paclitaxel (9.5 vs 6.3 months)2
IPA
SS
: P
rog
res
sio
n F
ree
Su
rviv
al (
EG
FR
M+
)PFS in the EGFR M+ population
EGFR M+HR=0.48, 95% CI 0.36, 0.64, p<0.0001
EGFR M-
HR=2.85, 95% CI 2.05, 3.98, p<0.0001
0 4 8 12 16 20 24Time from randomisation (months)
0.0
0.2
0.4
0.6
0.8
1.0IRESSA EGFR M+ (n=132)IRESSA EGFR M- (n=91)
Carboplatin / paclitaxel EGFR M+ (n=129)Carboplatin / paclitaxel EGFR M- (n=85)
Treatment by subgroup interaction test, p<0.0001
Pro
bab
ilit
y o
f P
FS
Mok T, Wu TL, Thongprasert S et al. N Engl J Med 2009; 361:947-995. Iressa SmPC
![Page 79: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/79.jpg)
71
1.1
47
23.5
0
10
20
30
40
50
60
70
80
E G F R M+ E G F R M-
Ove
rall
Res
pons
e R
ate
%
IRESSA Carboplatin / paclitaxel
EGFR M+ odds ratio (95% CI) = 2.75(1.65, 4.60), p=0.0001
EGFR M- odds ratio (95% CI) = 0.04(0.01, 0.27), p=0.0013
(n=132) (n=129) (n=91)(n=85)
IPA
SS
: O
ver
all
Res
po
ns
e R
ate
(E
GF
R M
+)
Superior ORR in the EGFR M+ population
Mok T, Wu TL, Thongprasert S et al. N Engl J Med 2009; 361:947-995Iressa SmPC
![Page 80: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/80.jpg)
The NEJ002 and WJTOG3405 studies
![Page 81: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/81.jpg)
Months since randomization
0
20
40
60
80
100Progression-free survival (%)
0 3 6 9 12 15 18 21 24 27
Carboplatin/
paclitaxel(n=110)
IRESSA(n=114)
Maemondo et al 2010
HR=0.30, 95% CI 0.22 - 0.41, p<0.001Median PFS : 10.8 vs 5.4 months
![Page 82: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/82.jpg)
Months since randomization
0
20
40
60
80
100Proportion without progression (%)
0 10 20 30 40
p<0.0001
8686
2211
43
20
00
6349
117
30
20
Number at riskIRESSA
Cisplatin and docetaxel
Mitsudomi et al 2010
86
9.2 months (8.0-13.0)
86
6.3 months (5.8-7.8)
n
Median PFS (95% CI)
IRESSA Cisplatin and
docetaxel
PFS: progression-free survival
HR=0.49, 95% CI 0.34-0.71; p<0.0001
![Page 83: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/83.jpg)
STUDY Line of Treatme
nt
EGFR M+ (n)
ORR (%) Median PFS
(months)
Median OS
(months)
Sequist et al 2008Journal of Clinical Oncology 2008;
26(15): 2442-2449
1st 31 55% 9.2m 17.5m
Cortes-Funes et al 2005
Annals of Oncology 2005; 16: 1081-1086
Pre-treated
10 60% 12.3m 13m
Cappuzzo et al 2007Journal of Clinical Oncology 2007;
25(16): 2248-55
Mixed 24 62% - -
Yang et al 2008Journal of Clinical Oncology 2008;
26(16): 2745-53
1st 55 69% 8m -
Tamura et al 2008British Journal of Cancer 2008;
98(5): 907-14
1st 28 75% 11.5m -
Sone et al 2007Cancer 2007; 109(9): 1836-44
Mixed 17 59% 7.3m 18.9m
Oshita et al 2006British Journal of Cancer 2006;
95(8): 1070-5
Mixed 11 91% - -
Costa et al 2007Lung Cancer 2007; 58(1): 95-103
Meta-analysis
99 81% 7.7 to 12.9m
Over 15.4m
IRE
SS
A:
Eff
ica
cy
Ind
ep
en
de
nt
of
Eth
nic
ity
AS
IA
NO
N-A
SIA
![Page 84: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/84.jpg)
• Understanding biology and biomarkers is key to improve the management of lung cancer
• Targeting the EGFR pathway represents a major advance in the management of NSCLC
• Mutation rates are low in the Western world (local population is ~ 5%)
![Page 85: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/85.jpg)
![Page 86: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/86.jpg)
KRAS genetics service 6th May 2010 – 2nd Dec 2010
Andrew Purvis, Clinical Scientist
Cheshire and Merseyside Regional Molecular Genetics Laboratory
Liverpool Women’s Hospital
![Page 87: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/87.jpg)
KRAS• KRAS – small GTPase
• Signal transducer downstream of EGFR (RAS/RAF/MAPK pathway)
• Regulator of cell proliferation and survival
• Somatic mutations in KRAS abolish GTPase activity = uncontrolled proliferation
• Pathway isolated from EGFR• Anti-EGFR therapy ineffective
• ~40% of mCRC have a somatic mutation in KRAS (e.g. CO.17)
PP
RAF
MEK
MAPK
EGF
EGFR
KRAS
Cell proliferation and survival
cell membrane
![Page 88: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/88.jpg)
KRAS – sequence and mutations
1 ATGACTGAATATAAACTTGTGGTAGTTGGAGCTGGTGGCGTAGGCAAGAGTGCCTTGAC .-M--T--E--Y--K--L--V--V--V--G--A--G--G--V--G--K--S--A--L--T 60 GATACAGCTAATTCAGAATCATTTTGTGGACGAATATGATCCAACAATAGAGGATTCCTA 20 --I--Q--L--I--Q--N--H--F--V--D--E--Y--D--P--T--I--E--D--S--Y 120 CAGGAAGCAAGTAGTAATTGATGGAGAAACCTGTCTCTTGGATATTCTCGACACAGCAGG 40 --R--K--Q--V--V--I--D--G--E--T--C--L--L--D--I--L--D--T--A--G 180 TCAAGAGGAGTACAGTGCAATGAGGGACCAGTACATGAGGACTGGGGAGGGCTTTCTTTG 60 --Q--E--E--Y--S--A--M--R--D--Q--Y--M--R--T--G--E--G--F--L--C 240 TGTATTTGCCATAAATAATACTAAATCATTTGAAGATATTCACCATTATAGAGAACAAAT 80 --V--F--A--I--N--N--T--K--S--F--E--D--I--H--H--Y--R--E--Q--I
>90% of mutations in mCRC found in codons 12 and 13~5% of mutations found in codon 61
![Page 89: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/89.jpg)
Pyrosequencing assay for detection of KRAS mutations at
LWH• Why Pyrosequencing?
• Unambiguous detection of ALL possible mutations in codons 12, 13 and 61
• Sensitive• Detects 5%-10% mutant depending on the mutation
• Results obtainable from DNA isolated from PETs• DNA of poor quality• DNA of low quantity
• Proven technology• Qualitative and quantitative analysis
![Page 90: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/90.jpg)
Example KRAS Pyrosequencing results
Gene sequence (codons 12 and 13)
Vis
ible
ligh
t
Non-mutated patient (normal sequence)
![Page 91: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/91.jpg)
KRAS mutation +ve and –ve results
c.34G>T, p.Gly12Cys
No mutation
c.38G>A, p.Gly13Asp
![Page 92: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/92.jpg)
KRAS testing 6th May 2010 to 2nd Dec 2010
• 28 referrals (cut sections or tissue blocks) from 5 pathology laboratories:• Arrowe Park 6• Chester 7• Royal Liverpool 3• Southport 8• Whiston 4
• KRAS results obtained for 28/28 referrals
![Page 93: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/93.jpg)
KRAS testing 6th May 2010 to 2nd Dec 2010
• Reporting times of 28 referrals• Mean reporting time 5.5 working days• 18 (64%) reported within 5 working days
KRAS reporting times
0
2
4
6
8
2 3 4 5 6 7 9 10Working days taken to report results
Nu
mb
er o
f re
ferr
als
![Page 94: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/94.jpg)
KRAS testing 6th May 2010 to 2nd Dec 2010
• 16/28 - no detectable KRAS mutation• 12/28 (43%) - detectable KRAS mutation
• 10 in codon 12• 2 in codon 13• 0 in codon 61
34G>T (Gly12Cys), 2
35G>T (Gly12Val), 6
35G>A (Gly12Asp), 2
38G>A (Gly13Asp) , 2
Normal, 16
Proportion of KRAS mutations detected
![Page 95: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/95.jpg)
Sensitivity / UKNEQAS (quality assessment scheme)
• Mutations can be present at low level• Tumour heterogeneity• Accompanying normal tissue
• Pyrosequencing detects mutations down to 5-10% depending on mutation
• Current mutation detection rate is 43% • Agrees with published data• Suggests we have not missed any mutations
• Full marks in recent UKNEQAS scheme• Not all participating labs received full marks• ? include % neoplastic cells on KRAS reports
![Page 96: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/96.jpg)
De Roock et al., JAMA. 2010;304(16):1812-1820
Do all KRAS mutations in codons 12, 13 and 61 have the same effect
on anti-EGFR therapy?
![Page 97: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/97.jpg)
BRAF V600E ?• A proportion of tumours with no KRAS
mutation will not respond to anti-EGFR therapy• Other biomarkers? • BRAF V600E detected in 5-12% of mCRC
• Same pathway as KRAS• V600E increases BRAF activity ~10 fold
• Predicts resistance to anti-EGFR therapy34G>T (Gly12Cys), 2
35G>T (Gly12Val), 6
35G>A (Gly12Asp), 2
38G>A (Gly13Asp) , 2
Normal, 16
![Page 98: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/98.jpg)
![Page 99: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/99.jpg)
Colorectal Cancer
Place of K-ras testing
![Page 100: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/100.jpg)
Colorectal Cancer
Stage Incidence 5yr survival
Dukes A 10% 90+%
Dukes B 22% 60-80%
Dukes C 39% 30-60%
Metastatic 29% <5%
65% of patients with CRC will eventually die from advanced disease
19,000pts annually in UK
![Page 101: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/101.jpg)
Systemic therapy for CRC
Best supportive care5FU
IrinotecanCapecitabine
Oxaliplatin
Cetuximab
Bevacizumab
1957 1994 2005
302520151050 Median survival - months
![Page 102: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/102.jpg)
Cetuximab - 2003
• Chimeric mouse monoclonal ab
• Targeted against EGFR receptor
• Entry point to signal transduction pathway
– cell proliferation
– cell migration
– cell adhesion
– cell survival
![Page 103: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/103.jpg)
EGFR signaling
Baselga. Eur J Cancer 2001;37 Suppl 4:S16-S22.
![Page 104: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/104.jpg)
Cetuximab
• active in CTX resistant colorectal xenografts
• synergistic with
– Irinotecan
– radiotherapy
![Page 105: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/105.jpg)
NCI of Canada ph III Cet vs BSC CO.17
572 pts, egfr expression +veNon responders to Ctx
Cetuximab BSCMS 6.1m 4.6mPR 8% 0%
![Page 106: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/106.jpg)
0
20
40
60
80
100
0 2 4 6 8 10 12
BOND studyTime to progression
Patients free of progression (%)
Time to progression (months)
Cunningham et al. N Engl J Med 2004; 351:337-345.
p<0.001
ERBITUX + irinotecan ERBITUX
![Page 107: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/107.jpg)
Cetuximab - Toxicity
• Acneiform rash
– Gd >1 76%
– Gd 3/4 12%
– maximal at wk3 then improves
– ? Rash associated with improved survival
![Page 109: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/109.jpg)
![Page 110: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/110.jpg)
CRYSTAL – Ph III Ist line
• 1198 pts
• FOLFIRI +/- cetuximab
Pfs 8.9m 8m
RR 47% 39%
OS 23.5m 20m ns
![Page 111: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/111.jpg)
COIN – first line 3 arm trial
• FOLFOX/XELOX + cet continuous
• FOLFOX/XELOX continuous
• FOLFOX/XELOX + cet intermittent
• 1630pts randomised
• No difference in OS or PFS
![Page 112: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/112.jpg)
EGFR expression
• Not a useful predictive factor– Heterogeneity of EGFR expression– Variable affinity of EGFR for cetuximab– Inconsistency in measurement
![Page 113: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/113.jpg)
K-ras oncogene
• Encode proteins downstream from EGFR
• Essential component of EGFR signalling
• Can acquire activating mutations in exon 2
• Does mutation status of K-ras affect response to anti-EGFR monoclonals?
![Page 114: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/114.jpg)
CO.17
394/572 samples available for K-ras analysis
K-ras mutation detected in 40%
![Page 115: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/115.jpg)
CO.17
Cetuximab BSC
Mutated ms 4.5m 4.6m1yr 13% 19%RR 1% 0%
Wild Type ms 9.5m 4.8m1yr 28% 20%RR 12% 0%
![Page 116: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/116.jpg)
CO.17 - Survival
![Page 117: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/117.jpg)
EGFR signaling
Baselga. Eur J Cancer 2001;37 Suppl 4:S16-S22.
![Page 118: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/118.jpg)
CRYSTAL K-ras WT pts
• Post hoc analysis for NICE (TA176)
• 348pts FOLFIRI + cetuximab
WT Mutant
PFS 9.9 8.7m p=0.0167
MS 24.9m 21 m ns
RR 66% 43% p=0.0028
Surgery 7% 3.7%
![Page 119: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/119.jpg)
COIN – WT analysis
• 729 WT pts OXFp +/- cetuximab
• PFS ns
• OS ns
• RR 64% vs 57% p=0.049
![Page 120: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/120.jpg)
OPUS – first line Ph II
• 336pts 134 K-ras WT
• FOLFOX +/- cetuximab
WT Mutant
PFS 7.7 m 7.2 m p=0.01
RR 60% 37% p = 0.011
Surgery 11% 4.1% sig not reported
![Page 121: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/121.jpg)
CELIM – first line
• Randomised ph II
• 114 pts
• Initially unresectable liver metastases
• folfiri + cetuximab vs folfox + cetuximab
• RR 68% vs 57%
• Subsequent resection 43 vs 40%
![Page 122: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/122.jpg)
1st line cetuximab + Ctx
• Variable effect on survival
• ? Consistently higher response rates
![Page 123: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/123.jpg)
Liver metastases - down sizing
• Systemic therapy may render tumours operable • 95/701 (13.5%) rendered resectable
– Reason unresectable• 60% (too large),
• 49% (ill located),
• 34% (multinodular),
• 18% (extrahepatic)
Inoperableliver metastasis
5yr survival< 5%
Chemotherapy
Operableliver metastasis
5yr survival 30-40%
Adam Ann Surg Oncol 2001
![Page 124: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/124.jpg)
0.0
0.2
0.4
0.6
0.8
1.0
0 1 2 3 4 5 6 7 8 9 10
Survival after chemotherapy-facilitated resection of metastases is the same as that for initially resectable metastases
Adam R. Ann Oncol 2003;14:ii13-ii16.
Proportion surviving
Survival time (years)
Resectable (n = 425) Initially unresectable (n = 95)
54%
50% 34%
34%
27%
29%19%
![Page 125: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/125.jpg)
Resection rate correlates with tumor response rate in both selected and non-selected patients
Studies including all patients with mCRC (solid line) (r=0.74, p<0.001)
Studies including selected patients(liver metastases only, no extrahepatic disease)(r=0.96, p=0.002)
Phase III studies including all patients in mCRC (dashed line)(r=0.67, p=0.024)
Folprecht et al. Ann Oncol 2005;16:1311-1319.
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.3 0.4 0.5 0.6 0.7 0.8 0.9
Resection rate
Response rate
![Page 126: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/126.jpg)
NICE guidance TA176
• Recommended Cetuximab + Chemotherapy for patients
– With inoperable CRC metastases confined to the liver– Who were fit for surgery– Who might be downsized to surgery following systemic therapy
![Page 127: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/127.jpg)
CCO – Survival from I-CET
44ptsMS 10m (6 – 13)
![Page 128: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/128.jpg)
CCO – Survival from 1st line CTX
44pts MS 36m (32 – 39)
![Page 129: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/129.jpg)
Xelox x 12 weeks
Nov 08
![Page 130: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/130.jpg)
Feb 09
![Page 131: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/131.jpg)
May 09
Irinotecan x 12 wks
![Page 132: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/132.jpg)
Oct 09
![Page 133: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/133.jpg)
Jan 10
I-Cetux
![Page 134: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/134.jpg)
![Page 135: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/135.jpg)
![Page 136: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/136.jpg)
Adjuvant Cetuximab
• FOLFOX +/- cetuximab
• NCCTG Intergroup phase III trial NO147
• 1760pts st III colon cancer wild type K-ras
Folfox Fotfox + cet
3yr dfs 74% 73%
3yr os 87% 82%
![Page 137: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/137.jpg)
Cetuximab 2010
• Downsizing liver metastases to resection In combination with oxaliplatin/5FU/Irinotecan
• Third line treatment in pts previously responding to chemotherapy In combination with Irinotecan
Adjuvant cetuximab not of value
![Page 138: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/138.jpg)
![Page 139: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/139.jpg)
The National Cancer Dataset Project
- especially pathology!Di Riley
Director for Clinical Outcomes
![Page 140: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/140.jpg)
.....Better information on cancer services and outcomes will enhance patient choice, drive up service quality and underpin stronger commissioning;
.....Collection of defined datasets on all cancer patients will be mandated through the national model contract. PCTs will be responsible for ensuring that this information is collected by MDTs and sent to cancer registries
CRS, December 2007
![Page 141: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/141.jpg)
.....We particularly need to collect anduse high quality data on:
.....Clinical outcomes, including survival, with adjustments for co-morbidity and stage of disease.
CRS, December 2007
![Page 142: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/142.jpg)
1020
3040
5060
Ris
k-ad
just
ed
AP
E r
ate
0 100 200 300 400 500Number of surgically treated rectal cancer patients
![Page 143: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/143.jpg)
Five-year relative survival for colorectal cancer patients (diagnosed 1996-2002) by stage at diagnosis, England
![Page 144: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/144.jpg)
Number of cases (1996-2006) and five-year relative survival of colorectal cancer patients (diagnosed 1996-2002) by stage at diagnosis, England
![Page 145: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/145.jpg)
Project Purpose
• To redevelop the National Cancer Dataset for use as a full operational standard in England
• To review the current business needs for the collections and make sure that the output is fit for purpose
![Page 146: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/146.jpg)
NCIN ‘Data Views’
Patient Pathway
Dat
aset
s/S
ou
rces
Refer-ral
Diag Stage Rx Rec/Mets Rx Pall. Care
Death
Diagnostics
CWT
MDT
RTDS
HES
NCASP
Ca. Reg
![Page 147: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/147.jpg)
SSCRG progress
• Approved mandated datasets– Cancer registration – additional review– GFoCW– Radiotherapy– CDS
• 12 SSCRGs identified ‘site specific’ items– Link to ‘output’ requirements– Based on existing datasets e.g. NCASP, BAUS– Period of definitional testing
• Mandated for NHS from October 2012
![Page 148: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/148.jpg)
Challenges....
• Clinical data from MDTs?• Transport via standard NHS data flows
– SUS, Open Exeter (Cancer Waits)– Direct Cancer Registries & Nat. Repository– Direct to NCASP
• Linking activity and ‘care record’ data– OPCDS + radiotherapy– CWT + ‘registration’– NHS number linked data views
• Coded data from path/radiology/etc
![Page 149: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/149.jpg)
Pathology Data
• Patient care & management– MDT– Staging– Ongoing care
• Cancer Outcomes/Registration– Staging– Morphology, topography, grade– Risk adjusted analysis
![Page 150: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/150.jpg)
NCRD – pathology items -1
DiagnosisDIAGNOSIS DATE (CANCER) PRIMARY DIAGNOSIS (ICD) TUMOUR LATERALITY BASIS OF DIAGNOSIS (CANCER) HISTOLOGY (SNOMED)
GRADE OF DIFFERENTIATION (AT DIAGNOSIS)
Staging
T CATEGORY (FINAL PRETREATMENT)
STAGING CERTAINTY FACTOR (T CATEGORY)
N CATEGORY (FINAL PRETREATMENT)
STAGING CERTAINTY FACTOR (N CATEGORY)
M CATEGORY (FINAL PRETREATMENT)
STAGING CERTAINTY FACTOR (M CATEGORY)
TNM CATEGORY (FINAL PRETREATMENT)
STAGING CERTAINTY FACTOR (TNM CATEGORY)
SITE SPECIFIC STAGING CLASSIFICATION
TNM CATEGORY (INTEGRATED)
T CATEGORY (INTEGRATED STAGE)
N CATEGORY (INTEGRATED STAGE)
M CATEGORY (INTEGRATED STAGE)
![Page 151: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/151.jpg)
Pathology DetailsPATHOLOGY INVESTIGATION TYPE SAMPLE RECEIPT DATE INVESTIGATION RESULT DATE CONSULTANT CODE (PATHOLOGIST) ORGANISATION CODE (OF REPORTING PATHOLOGY) PRIMARY DIAGNOSIS (ICD) TUMOUR LATERALITY INVASIVE LESION SIZE SYNCHRONOUS TUMOUR INDICATOR HISTOLOGY (SNOMED) GRADE OF DIFFERENTIATION CANCER VASCULAR OR LYMPHATIC INVASION EXCISION MARGIN NODES EXAMINED NUMBER NODES POSITIVE NUMBER T CATEGORY (PATHOLOGICAL) N CATEGORY (PATHOLOGICAL) M CATEGORY (PATHOLOGICAL) TNM CATEGORY (PATHOLOGICAL) SERVICE REPORT IDENTIFIER SERVICE REPORT STATUS SPECIMEN NATURE ORGANISATION CODE (REQUESTED BY) CARE PROFESSIONAL CODE (REQUESTED BY) T CATEGORY EXTENDED (PATHOLOGICAL) M CATEGORY EXTENDED (PATHOLOGICAL)
NCRD – pathology items -2
![Page 152: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/152.jpg)
RCPath Datasets
• Guidelines for good clinical reporting– Specific for different cancer sites
• What proportion of pathologists use proforma-based reporting tools?
• How to or should we progress to encoded data?• Cancer registration & outcomes analysis would
benefit from it?• Would MDTs also benefit - MDT dataset?
![Page 153: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/153.jpg)
NCIN/RCPath Pathology Project
• Structured or proforma reporting• Codify & mandate ‘Core’ items• Direction of travel too great
– Systems not available– Change in clinical practice– Patient management v outcomes analysis
• What is the solution?– Professional & Clinical Record Standards
![Page 154: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/154.jpg)
• Clarification of content to be provided within free text reports (RCPAth Core Items)
• Or the use of the RC Path proforma.
• Communication to Pathologists of content specification and mechanism for transmission to Registries.
• Both of these aspects covered by RC Path guidance
Professional Standard -Stage 1
![Page 155: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/155.jpg)
• Professional Standard version 2– stipulation of proforma to be used for
reporting– introduction of structured/coded items
• Patient Record Standard version 1– identification of items which can be
structured and have SNOMED CT codes
Standards - Stage 2
![Page 156: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/156.jpg)
• Professional Standard version 3 – structured data items
• Patient Record Standard version 2 – all items structured with SNOMED CT
coding– identification of the linkage standards to
allow record to Registry transmission and use.
Standards - Stage 3
![Page 157: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/157.jpg)
Timescales & Process
• Working Group– RCPath / NCIN / CfH /DH– National Clinical Content & Requirements Board (NCCRB)– Role of RCPath for governance key– Align with other related initiatives
• Estimated time – 5 years (2015)– Content Proposal – approved November 2010– Requirements Statement– Assurance Statement– Then the Information Standards Board
![Page 158: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/158.jpg)
1020
3040
5060
Ris
k-ad
just
ed
AP
E r
ate
0 100 200 300 400 500Number of surgically treated rectal cancer patients
![Page 159: A study into the urgent endoscopy referral system for patients with suspected gastrointestinal cancer Christopher Jump 3 rd Year Medical Student](https://reader038.vdocuments.site/reader038/viewer/2022103123/56649d0d5503460f949e213d/html5/thumbnails/159.jpg)